New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Can-Fite Biopharma Ltd (CANF) vs Heatwurx Inc. (PCSA)

Can-Fite Biopharma Ltd and Heatwurx Inc. are both Biotechnology companies. Can-Fite Biopharma Ltd and Heatwurx Inc. are of similar size ($4.8M and $4.6M). Can-Fite Biopharma Ltd grew revenue faster over the last twelve months: −3.36% against −34.5%. Heatwurx Inc. has the higher net margin (0.00% vs −1,148.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Heatwurx Inc. leads on 7 and Can-Fite Biopharma Ltd on 5.

Valuation

Metric CANF PCSA Biotechnology median
P/E n/m n/m 8.26
P/S 0.37 37.91 9.20
P/B 0.06 n/m 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.59 0.90 0.67
EV/Sales (8.71) (1,326.40) 9.05
Earnings yield (884.72%) (3,520.03%) (34.24%)
Free cash flow yield (6,631.35%) (298.72%) (24.77%)

Profitability

Metric CANF PCSA Biotechnology median
Gross margin 0.00% 0.00% 70.18%
Operating margin 0.00% 0.00% 0.00%
Net margin (1,148.62%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 220.06% (51.58%)
Return on assets 0.00% (203.76%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CANF PCSA Biotechnology median
Revenue growth (TTM) (3.36%) (34.50%) 7.20%
EPS growth (last fiscal year) 45.23% 89.29% 29.04%
Revenue growth, 5-year CAGR (11.90%) — 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CANF PCSA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.60 97.70 4.83
Net debt to EBITDA 0.86 0.40 1.01

Dividend

Metric CANF PCSA Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric CANF PCSA Biotechnology median
Market cap 4.61m 4.76m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack